Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.7 USD | 0.00% | +0.59% | +6.25% |
May. 16 | Reneo Pharmaceuticals Insider Bought Shares Worth $639,578, According to a Recent SEC Filing | MT |
May. 13 | Reneo Pharmaceuticals to Merge With OnKure in All-Stock Deal -- Reneo Shares Rise | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 56.82M |
---|---|---|---|---|---|
Net income 2024 * | -22M | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-2.62
x | P/E ratio 2025 * |
-
| Employees | 8 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.86% |
1 week | +0.59% | ||
Current month | +2.41% | ||
1 month | -2.30% | ||
3 months | +3.66% | ||
6 months | -75.43% | ||
Current year | +6.25% |
Managers | Title | Age | Since |
---|---|---|---|
Niall O'Donnell
FOU | Founder | 51 | - |
Gregory Flesher
CEO | Chief Executive Officer | 54 | 20-12-08 |
Michael Grey
FOU | Founder | 71 | 14-09-21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Grey
FOU | Founder | 71 | 14-09-21 |
Director/Board Member | 64 | 17-11-30 | |
Paul Hoelscher
BRD | Director/Board Member | 59 | 22-01-19 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.49% | 4 M€ | -5.15% | - | |
0.00% | 34 M€ | +4.23% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-06 | 1.7 | 0.00% | 66,309 |
24-06-05 | 1.7 | +2.41% | 68,257 |
24-06-04 | 1.66 | -0.60% | 47,622 |
24-06-03 | 1.67 | +0.60% | 38,485 |
24-05-31 | 1.66 | -3.49% | 108,667 |
Delayed Quote Nasdaq, June 06, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.25% | 56.82M | |
+55.55% | 59.34B | |
+43.17% | 40.24B | |
-4.71% | 39.88B | |
-5.56% | 28.55B | |
+13.76% | 27.26B | |
-22.00% | 19.23B | |
+31.50% | 12.61B | |
+2.16% | 12.49B | |
+25.70% | 12.28B |
- Stock Market
- Equities
- RPHM Stock